(NASDAQ: BLTE) Belite Bio's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.57%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.16%.
Belite Bio's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast BLTE's revenue for 2024 to be $1,457,472,200, with the lowest BLTE revenue forecast at $1,457,472,200, and the highest BLTE revenue forecast at $1,457,472,200. On average, 1 Wall Street analysts forecast BLTE's revenue for 2025 to be $728,736,100, with the lowest BLTE revenue forecast at $728,736,100, and the highest BLTE revenue forecast at $728,736,100.
In 2026, BLTE is forecast to generate $874,483,320 in revenue, with the lowest revenue forecast at $874,483,320 and the highest revenue forecast at $874,483,320.